In technology that promises to one day allow drug delivery to be tailored to an individual patient and a particular cancer tumor, researchers at the University of California, San Diego School of ...
When new protein structures are reported, it’s often claimed they could lead to the design of therapeutic agents that interact with the proteins more effectively. A new study on short interfering RNAs ...
VANCOUVER, British Columbia, April 12, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced ...
We are enthusiastic to join forces with Madrigal Pharmaceuticals, drawing on their extensive knowledge together with our siRNA expertise to advance life changing therapies for people affected by liver ...
US biopharma Madrigal Pharmaceuticals, which is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), has announced an exclusive global license ...
LAFAYETTE, Colo.-- The Genome-Wide RNAi Global Initiative (RNAi Global), an alliance of Dharmacon, Inc., and 14 leading international research centers pioneering the use of whole-genome RNAi screening ...
Ribo and Ribocure enter exclusive global licensing agreement with Madrigal for novel siRNA therapeutics targeting MASH: Suzhou, China Thursday, February 12, 2026, 15:00 Hrs [IST] ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results